MedTrace Logo

Safety and Immunogenicity of AdCOVID in Healthy Adults (COVID-19 Vaccine Study)

NCT04679909 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 92

Last updated 2023-08-14

No results posted yet for this study

Summary

A study to evaluate the immune response and safety of AdCOVID administered as an intranasal spray in healthy adults.

Conditions

  • Healthy Volunteers

Interventions

BIOLOGICAL

AdCOVID

Administered intranasally

OTHER

Placebo

Administered intranasally

Sponsors & Collaborators

  • Altimmune, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-02-25
Primary Completion
2021-12-01
Completion
2022-12-21
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04679909 on ClinicalTrials.gov